

Executive Branch Personnel

Public Financial Disclosure Report:

Periodic Transaction Report (OGE Form 278-T)

Filer's Information

Lyon, Andrew

Special Assistant to the President for Economic Policy, Trump-Vance (2025) - White House

Electronic Signature - I certify that the statements I have made in this form are true, complete and correct to the best of my knowledge.

/s/ Lyon, Andrew [electronically signed on 03/28/2025 by Lyon, Andrew in Integrity.gov] - Filer received a 30 day filing extension.

Agency Ethics Official's Opinion - On the basis of information contained in this report, I conclude that the filer is in compliance with applicable laws and regulations (subject to any comments below).

/s/ Jones, David M, Certifying Official [electronically signed on 04/02/2025 by Jones, David M in Integrity.gov]

Other review conducted by

/s/ Jones, David M, Ethics Official [electronically signed on 04/02/2025 by Jones, David M in Integrity.gov]

U.S. Office of Government Ethics Certification

Data Revised

Transactions

#	DESCRIPTION		TYPE	DATE	NOTIFICATION RECEIVED OVER 30 DAYS AGO	AMOUNT
1	DEXCOM INC	See Endnote	Sale	02/14/2025	Yes	\$15,001 - \$50,000
2	DEXCOM INC	See Endnote	Sale	02/14/2025	Yes	\$1,001 - \$15,000
3	ADOBE INC		Sale	03/14/2025	No	\$1,001 - \$15,000
4	BOEING CO		Sale	03/14/2025	No	\$15,001 - \$50,000
5	BEST BUY CO INC	See Endnote	Sale	02/11/2025	Yes	\$1,001 - \$15,000
6	MODERNA INC		Sale	03/14/2025	No	\$1,001 - \$15,000
7	FEDEX CORP	See Endnote	Sale	02/13/2025	Yes	\$15,001 - \$50,000
8	BLACKSTONE INC		Sale	03/14/2025	No	\$1,001 - \$15,000
9	ADOBE INC	See Endnote	Sale	02/12/2025	Yes	\$15,001 - \$50,000
10	MODERNA INC	See Endnote	Sale	02/18/2025	Yes	\$1,001 - \$15,000
11	GE AEROSPACE	See Endnote	Sale	02/12/2025	Yes	\$15,001 - \$50,000
12	GE HEALTHCARE TECHNOLOGIES INC	See Endnote	Sale	02/13/2025	Yes	\$1,001 - \$15,000
13	WELLS FARGO & CO	See Endnote	Sale	02/14/2025	Yes	\$15,001 - \$50,000
14	GSK PLC ADR FSPONSORED ADR	See Endnote	Sale	02/12/2025	Yes	\$1,001 - \$15,000
15	LVMH MOET HENNESSY ADR	See Endnote	Sale	02/12/2025	Yes	\$15,001 - \$50,000
16	BP P L C FSPONSORED ADR	See Endnote	Sale	02/12/2025	Yes	\$15,001 - \$50,000
17	BCE INC	See Endnote	Sale	02/12/2025	Yes	\$15,001 - \$50,000
18	LIBERTY BROADBAND CORP CLASS A	See Endnote	Sale	02/12/2025	Yes	\$15,001 - \$50,000
19	SKYWORKS SOLUTIONS INC	See Endnote	Sale	02/12/2025	Yes	\$15,001 - \$50,000

#	DESCRIPTION		TYPE	DATE	NOTIFICATION RECEIVED OVER 30 DAYS AGO	AMOUNT
20	GRUPO TELEVIS A B FTRADES WITH DUE BILLS	See Endnote	Sale	02/12/2025	Yes	\$1,001 - \$15,000
21	CVS HEALTH CORP	See Endnote	Sale	02/12/2025	Yes	\$1,001 - \$15,000
22	MAGNA INTL INC	See Endnote	Sale	02/12/2025	Yes	\$15,001 - \$50,000
23	CNH INDL N V	See Endnote	Sale	02/12/2025	Yes	\$15,001 - \$50,000
24	WALGREENS BOOTS ALLIANCE	See Endnote	Sale	02/13/2025	Yes	\$1,001 - \$15,000
25	VIATRIS INC	See Endnote	Sale	02/13/2025	Yes	\$1,001 - \$15,000
26	ADOBE INC	See Endnote	Sale	02/13/2025	Yes	\$15,001 - \$50,000
27	PRA GROUP INC	See Endnote	Sale	02/14/2025	Yes	\$1,001 - \$15,000
28	CONAGRA BRANDS INC	See Endnote	Sale	02/14/2025	Yes	\$1,001 - \$15,000
29	DEXCOM INC	See Endnote	Sale	02/14/2025	Yes	\$15,001 - \$50,000
30	HEXCEL CORP NEW	See Endnote	Sale	02/18/2025	Yes	\$15,001 - \$50,000
31	APA CORP	See Endnote	Sale	02/18/2025	Yes	\$1,001 - \$15,000
32	PFIZER INC	See Endnote	Sale	02/20/2025	Yes	\$1,001 - \$15,000
33	MERCK & CO. INC.	See Endnote	Sale	02/20/2025	Yes	\$1,001 - \$15,000
34	CROWN CASTLE INC REIT	See Endnote	Sale	02/21/2025	Yes	\$1,001 - \$15,000
35	REGIONS FINL CORP NEW		Sale	03/14/2025	No	\$1,001 - \$15,000
36	EXXON MOBIL CORP		Sale	03/14/2025	No	\$15,001 - \$50,000

Endnotes

PART	#	ENDNOTE
Transactions	1	30-day extension received

PART	#	ENDNOTE
Transactions	2	30-day extension received
Transactions	5	30-day extension received
Transactions	7	30-day extension received
Transactions	9	30-day extension received
Transactions	10	30-day extension received
Transactions	11	30-day extension received
Transactions	12	30-day extension received
Transactions	13	30-day extension received
Transactions	14	30-day extension received
Transactions	15	30-day extension received
Transactions	16	30-day extension received
Transactions	17	30-day extension received
Transactions	18	30-day extension received
Transactions	19	30-day extension received
Transactions	20	30-day extension received
Transactions	21	30-day extension received
Transactions	22	30-day extension received
Transactions	23	30-day extension received
Transactions	24	30-day extension received
Transactions	25	30-day extension received
Transactions	26	30-day extension received
Transactions	27	30-day extension received

PART	#	ENDNOTE
Transactions	28	30-day extension received
Transactions	29	30-day extension received
Transactions	30	30-day extension received
Transactions	31	30-day extension received
Transactions	32	30-day extension received
Transactions	33	30-day extension received
Transactions	34	30-day extension received

Summary of Contents

The 278-T discloses purchases, sales, or exchanges of securities in excess of \$1,000 made on behalf of the filer, the filer's spouse, or dependent child. Transactions are required to be disclosed within 30 days of receiving notification of a transaction but not later than 45 days after the transaction. Filers need not disclose (1) mutual funds and other excepted investment funds; (2) certificates of deposit, savings or checking accounts, and money market accounts; (3) U.S. Treasury bills, notes, and bonds; (4) Thrift Savings Plan accounts; (5) real property; and (6) transactions that are solely by and between the filer, the filer's spouse, and the filer's dependent children.

Privacy Act Statement

5 U.S.C. § 13101 et seq., and 5 C.F.R. Part 2634 of the U. S. Office of Government Ethics regulations require the reporting of this information. Failure to provide the requested information may result in separation, disciplinary action, or civil action. The primary use of the information on this report is for review by Government officials to determine compliance with applicable Federal laws and regulations. This report may also be disclosed upon request to any requesting person in accordance with 5. U.S.C § 13107 and § 13122(b)(1) or as otherwise authorized by law. You may inspect applications for public access of your own form upon request. Additional disclosures of the information on this report may be made: (1) to any requesting person, subject to the limitation contained in section 208(d)(1) of title 18, any determination granting an exemption pursuant to sections 208(b)(1) and 208(b)(3) of title 18; (2) to a Federal, State, or local law enforcement agency if the disclosing agency becomes aware of violations or potential violations of law or regulation; (3) to a source when necessary to obtain information relevant to a conflict of interest investigation or determination; (4) to the National Archives and Records Administration or the General Services Administration in records management inspections; (5) to the Office of Management and Budget during legislative coordination on private relief legislation; (6) when the disclosing agency determines that the records are arguably relevant to a proceeding before a court, grand jury, or administrative or adjudicative body, or in a proceeding before an administrative or adjudicative body when the adjudicator determines the records to be relevant to the proceeding; (7) to reviewing officials in a new office, department or agency when an employee transfers or is detailed from one covered position to another, a public financial disclosure report and any accompanying documents, including statements notifying an employee's supervising ethics office of the commencement of negotiations for future employment or compensation or of an agreement for future employment or compensation; (8) to a Member of Congress or a congressional office in response to an inquiry made on behalf of and at the request of an individual who is the subject of the record; (9) to contractors and other non-Government employees working on a contract, service or assignment for the Federal Government when necessary to accomplish a function related to this system of records; (10) on the OGE Website and to any person, department or agency, any written ethics agreement, including certifications of ethics agreement compliance, filed with OGE by an individual nominated by the President to a

position requiring Senate confirmation; (11) on the OGE Website and to any person, department or agency, any certificate of divestiture issued by OGE; (12) on the OGE Website and to any person, department or agency, any waiver of the restrictions contained in Executive Order 13989 or any superseding executive order; (13) to appropriate agencies, entities and persons when there has been a suspected or confirmed breach of the system of records, the agency maintaining the records has determined that there is a risk of harm to individuals, the agency, the Federal Government, or national security, and the disclosure is reasonably necessary to assist in connection with the agency's efforts to respond to the suspected or confirmed breach or to prevent, minimize, or remedy such harm; and (14) to another Federal agency or Federal entity, when the agency maintaining the record determines that information from this system of records is reasonably necessary to assist the recipient agency or entity in responding to a suspected or confirmed breach or in preventing, minimizing, or remedying the risk of harm to individuals, the recipient agency or entity, the Federal Government, or national security. See also the OGE/GOVT-1 executive branch-wide Privacy Act system of records.
